InMed Pharmaceuticals Inc.
INM · XNASCIK 1728328fmd_1A47FQ1QX1QZADESTC9WQJHZ3PManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jul 01, 2019 to Sep 30, 2026, 29 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|
| Total revenues | – | 2 | 1 | 4 | 5 | 5 | – |
| Net interest income | – | (0) | – | – | – | – | – |
| Cost of revenue | – | – | 1 | 3 | 3 | 3 | – |
| Gross profit | – | – | 1 | 1 | 1 | 2 | – |
| Research and development | 6 | 5 | 7 | 4 | 3 | 3 | 3 |
| Total operating expenses | 9 | 10 | 18 | 10 | 9 | 8 | 12 |
| Impairment of real estate | – | – | 1 | – | – | – | – |
| Operating income | – | (10) | (19) | (8) | (8) | (7) | – |
| Interest and investment income | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Other non-operating income (expense) | – | (0) | (1) | 0 | 1 | – | – |
| Income before taxes | – | – | (19) | (8) | (8) | (9) | (11) |
| Income tax expense | – | – | – | 0 | 0 | – | – |
| Net income from continuing operations | – | – | – | (8) | (8) | (9) | (11) |
| Net income | (9) | (10) | (19) | (8) | (8) | (2) | (13) |
| Net income to common shareholders | – | – | – | – | – | (8) | (13) |